Niti Aayog working on blockchain tech for drug industry
Niti Aayog is working with Apollo Hospitals and information technology major Oracle on applying blockchain technology in pharmaceutical supply chain management to detect spurious drugs, informed NITI Aayog’s CEO, Mr. Amitabh Kant.
Addressing a gathering through video-conferencing at the inaugural session of International Blockchain Congress 2018 held in Hyderabad recently, Mr. Kant said the organisation was working on applying the blockchain technology to pressing problems of the country in areas such as land registry, health records and fertiliser subsidy distribution, among others.
“There is a need to use blockchain to track and trace medicines and spurious drugs. Therefore, Niti Aayog, in collaboration with Apollo Hospitals and Oracle, is putting pharmaceutical supply chain in blockchain for complete traceability of drugs from manufacturer to consumer to protect our citizens from the menace of spurious medicines,” he said.
Looking for chemical products? Let suppliers reach out to you!
2026-07-15
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India’s API Trade Balance Turns Positive
-
BioNTech’s Founders Turn the Page
-
Novo Nordisk Faces a Compliance Test
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
Recommend Reading
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
Supply and Demand in Delicate Balance, Acrylonitrile Market Remains Stagnant in August in China
-
Your Plant Has the Data. Your AI Cannot Reach It. Here Is Why That Is the Core Problem in Chemical Manufacturing.
-
Hengli Sanctions Spill Over: One Barrel of Iranian Crude Pulls an Aromatics Chain Into Risk
-
EU Plans Broader Quotas and Tariffs on China, With Chemicals Clearly Named
-
Chemicals Are Going Wild: Sulfur Surges 512%, Titanium Dioxide, Polyols and Sulfuric Acid Lose Control